levetiracetam + Placebo + Levetriracetam
Phase 2/3Completed 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Traumatic Stress Disorder
Conditions
Post-Traumatic Stress Disorder
Trial Timeline
Nov 1, 2005 → Mar 1, 2008
NCT ID
NCT00413296About levetiracetam + Placebo + Levetriracetam
levetiracetam + Placebo + Levetriracetam is a phase 2/3 stage product being developed by UCB for Post-Traumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00413296. Target conditions include Post-Traumatic Stress Disorder.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00413296 | Phase 2/3 | Completed |
Competing Products
16 competing products in Post-Traumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 77 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| AMG 334 | Novartis | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |
| PF-04457845 + Placebo | Pfizer | Phase 2 | 51 |
| Zoloft (Sertraline) | Pfizer | Phase 3 | 76 |
| Levetiracetam + Placebo | UCB | Phase 3 | 74 |
| Placebo + Brexpiprazole | Lundbeck | Phase 3 | 74 |
| Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo | Lundbeck | Phase 2 | 49 |
| AbobotulinumtoxinA + Normal saline | Ipsen | Approved | 82 |
| Nabiximols + Placebo | Jazz Pharmaceuticals | Phase 2/3 | 62 |
| 60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114 | Praxis Precision Medicines | Phase 2 | 49 |
| MDMA | Nautilus Biotechnology | Phase 2 | 44 |
| Tramadol + Placebo | Brain Biotech | Approved | 77 |